511 related articles for article (PubMed ID: 12126818)
1. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.
Bolla M; Collette L; Blank L; Warde P; Dubois JB; Mirimanoff RO; Storme G; Bernier J; Kuten A; Sternberg C; Mattelaer J; Lopez Torecilla J; Pfeffer JR; Lino Cutajar C; Zurlo A; Pierart M
Lancet; 2002 Jul; 360(9327):103-6. PubMed ID: 12126818
[TBL] [Abstract][Full Text] [Related]
2. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.
Bolla M; Van Tienhoven G; Warde P; Dubois JB; Mirimanoff RO; Storme G; Bernier J; Kuten A; Sternberg C; Billiet I; Torecilla JL; Pfeffer R; Cutajar CL; Van der Kwast T; Collette L
Lancet Oncol; 2010 Nov; 11(11):1066-73. PubMed ID: 20933466
[TBL] [Abstract][Full Text] [Related]
3. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.
Bolla M; Gonzalez D; Warde P; Dubois JB; Mirimanoff RO; Storme G; Bernier J; Kuten A; Sternberg C; Gil T; Collette L; Pierart M
N Engl J Med; 1997 Jul; 337(5):295-300. PubMed ID: 9233866
[TBL] [Abstract][Full Text] [Related]
4. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
Denham JW; Steigler A; Lamb DS; Joseph D; Turner S; Matthews J; Atkinson C; North J; Christie D; Spry NA; Tai KH; Wynne C; D'Este C
Lancet Oncol; 2011 May; 12(5):451-9. PubMed ID: 21440505
[TBL] [Abstract][Full Text] [Related]
5. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
6. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
[TBL] [Abstract][Full Text] [Related]
7. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.
Denham JW; Steigler A; Lamb DS; Joseph D; Mameghan H; Turner S; Matthews J; Franklin I; Atkinson C; North J; Poulsen M; Christie D; Spry NA; Tai KH; Wynne C; Duchesne G; Kovacev O; D'Este C;
Lancet Oncol; 2005 Nov; 6(11):841-50. PubMed ID: 16257791
[TBL] [Abstract][Full Text] [Related]
8. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
[TBL] [Abstract][Full Text] [Related]
9. Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31. Radiation Therapy Oncology Group.
Corn BW; Winter K; Pilepich MV
Urology; 1999 Sep; 54(3):495-502. PubMed ID: 10475361
[TBL] [Abstract][Full Text] [Related]
10. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31.
Lawton CA; Winter K; Grignon D; Pilepich MV
J Clin Oncol; 2005 Feb; 23(4):800-7. PubMed ID: 15681524
[TBL] [Abstract][Full Text] [Related]
11. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.
Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1439-44. PubMed ID: 19540066
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer.
Bolla M
Eur Urol; 1999; 35 Suppl 1():23-5; discussion 26. PubMed ID: 10081699
[TBL] [Abstract][Full Text] [Related]
13. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group.
Pilepich MV; Krall JM; al-Sarraf M; John MJ; Doggett RL; Sause WT; Lawton CA; Abrams RA; Rotman M; Rubin P
Urology; 1995 Apr; 45(4):616-23. PubMed ID: 7716842
[TBL] [Abstract][Full Text] [Related]
14. Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10.
Shipley WU; Lu JD; Pilepich MV; Heydon K; Roach M; Wolkov HB; Sause WT; Rubin P; Lawton CA; Machtay M
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1302-10. PubMed ID: 12459350
[TBL] [Abstract][Full Text] [Related]
15. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
[TBL] [Abstract][Full Text] [Related]
16. [Indications of the association of radiotherapy and hormonal treatment in prostate cancer].
Bolla M; Maingon P; Fourneret P; Artignan X; Descotes JL
Cancer Radiother; 2005 Nov; 9(6-7):394-8. PubMed ID: 16226044
[TBL] [Abstract][Full Text] [Related]
17. [Current studies of combined radiotherapy-hormone therapy in localized and locally advanced prostatic cancers].
Bolla M; Artignan X; Chirpaz E; Balosso J; Descotes JL
Cancer Radiother; 1998 Dec; 2(6):783-6. PubMed ID: 9922789
[TBL] [Abstract][Full Text] [Related]
18. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.
Pilepich MV; Winter K; Lawton CA; Krisch RE; Wolkov HB; Movsas B; Hug EB; Asbell SO; Grignon D
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1285-90. PubMed ID: 15817329
[TBL] [Abstract][Full Text] [Related]
19. Penile length changes in men treated with androgen suppression plus radiation therapy for local or locally advanced prostate cancer.
Haliloglu A; Baltaci S; Yaman O
J Urol; 2007 Jan; 177(1):128-30. PubMed ID: 17162022
[TBL] [Abstract][Full Text] [Related]
20. Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Radiation Therapy Oncology Group.
Lawton CA; Winter K; Byhardt R; Sause WT; Hanks GE; Russell AH; Rotman M; Porter A; McGowan DG; DelRowe JD; Pilepich MV
Int J Radiat Oncol Biol Phys; 1997 Jul; 38(5):931-9. PubMed ID: 9276357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]